These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23203082)

  • 1. Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?
    Jalilian B; Einarsson HB; Vorup-Jensen T
    Int J Mol Sci; 2012 Nov; 13(11):14579-605. PubMed ID: 23203082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
    CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.
    Weber MS; Hohlfeld R; Zamvil SS
    Neurotherapeutics; 2007 Oct; 4(4):647-53. PubMed ID: 17920545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolving Mechanisms of Action of Glatiramer Acetate.
    Prod'homme T; Zamvil SS
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
    Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
    BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.
    Peterka M; Valis M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Klimova B; Stourac P; Pavelek Z; Novotny M
    Eur Neurol; 2023; 86(5):334-340. PubMed ID: 37473734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice.
    Mitsikostas D; Bakirtzis C; Nikolaidis I; Tsimourtou V; Kountra P; Matsi S; Papadimitriou A
    Neurodegener Dis Manag; 2022 Dec; 12(6):311-322. PubMed ID: 36178000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.
    Johnson KP
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):643-60. PubMed ID: 20397968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
    Arnon R; Aharoni R
    J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
    Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD
    Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate.
    Erzina D; Capecchi A; Javor S; Reymond JL
    Angew Chem Int Ed Engl; 2021 Dec; 60(50):26403-26408. PubMed ID: 34618395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S; Abramczyk S; Lisak D; Lisak R
    Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.
    Kuerten S; Jackson LJ; Kaye J; Vollmer TL
    CNS Drugs; 2018 Nov; 32(11):1039-1051. PubMed ID: 30315499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.